drugset / Trial / NCT00555022
Effect of GSK1160724 In Healthy Volunteers
RandomizedCrossoverTreatment
Summary
GSK1160724 is a potent mAChR antagonist, which is being developed for treatment of chronic obstructive pulmonary disease (COPD)
Timeline
- Start
- 2007-12-12
- Primary completion
- 2008-04-07
- Completion
- 2008-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Revefenacin | Small molecule | 10 ug | Inhaled |
| Subject | Revefenacin | Small molecule | 50 ug | Inhaled |
| Subject | Revefenacin | Small molecule | 125 ug | Inhaled |
| Subject | Tiotropium | Other / unclassified | 18 ug | Inhaled |